03347.HK
Hangzhou Tigermed Consulting Co., Ltd.
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 39.70
−0.25%Year over year
Reported trailing growth
- Revenue
- +12.1%
- EBITDA
- +235.8%
- EBIT
- +183.2%
- EPS
- -70.6%
- Free cash flow
- +79.1%
- Operating cash flow
- +248.6%
Forward estimates
Based on analyst estimates
- Revenue
- -44.2%
- EBITDA
- -48.2%
- EPS
- +566.8%
Three-year CAGR
- Revenue
- -1.2%
- EBITDA
- -21.5%
- EBIT
- -26.9%
- Net income
- -23.8%
- EPS
- -23.7%
- Free cash flow
- -0.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026